QURE

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Wall Street analysts forecast QURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QURE is 62.60 USD with a low forecast of 38.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Uniqure NV revenue for the last quarter amounts to 3.70M USD, increased 61.83 % YoY.

Uniqure NV. EPS for the last quarter amounts to -1.38 USD, increased 51.65 % YoY.

Uniqure NV (QURE) has 209 emplpoyees as of December 18 2025.

Today QURE has the market capitalization of 1.43B USD.